New drug hope for rare blood disorder that causes anemia in cold weather
NCT ID NCT06067048
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce anemia and cold-related symptoms by targeting the abnormal immune cells. Participants take zanubrutinib capsules daily for up to 36 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (Brukinsa)
What this could lead to
If successful, this could offer a new treatment option for cold agglutinin disease that targets both anemia and cold-induced symptoms, potentially improving quality of life.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The drug may cause side effects or fail to improve symptoms significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta
Roeselare, Belgium
-
Amsterdan UMC ( location AMC)
Amsterdam, Netherlands
-
Erasusmc
Rotterdam, Netherlands
-
Haukeland University Hospital Bergen
Bergen, Norway
-
Odense University Hospital
Odense, Denmark
-
Oslo University Hospital
Oslo, Norway
-
Rigshospitalet
Copenhagen, Denmark
-
UMCG
Groningen, Netherlands
-
UZ leuven
Leuven, Belgium
-
st. Olavs Hospital
Trondheim, Norway